ArticleTranslational lung cancer research2025
Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review of Management of Clinical Stage I Small Cell Lung Cancer: The Rising Role of Surgical Resection.Cancers · 2026Review
- Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer. The emergence of chemoimmunotherapy has changed the mode of SCLC treatment. However, in limited-stage SCLC (LS-SCLC), the effectiveness and safety of chemoimmunotherapy in the neoadjuvant setting for LS-SCLC are not well-established. To address this gap, we conducted a study to evaluate neoadjuvant chemoimmunotherapy in LS-SCLC. Methods: A retrospective study was conducted on patients from Beijing Chest Hospital, Capital Medical University, who underwent etoposide-based chemotherapy with programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) inhibitors (neoCIT group) or without (neoCT group) prior to surgery for LS-SCLC between April 2019 and March 2023. The primary endpoints were to evaluate the major pathological response (MPR) and the pathological complete response (pCR). Secondary endpoints comprised event-free survival (EFS), overall survival (OS), and safety. Results: A total of 31 patients with stage IIB-IIIB LS-SCLC were included, comprising 16 cases in the neoCIT group and 15 patients in the neoCT group. A pCR was observed in eight cases [50.0%; 95% confidence interval (CI): 28.0 to 72.0] within the neoCIT group, compared to one patient (6.7%; 95% CI: 0.3 to 29.8) in the neoCT group (odds ratio, 14.00; 95% CI: 1.71 to 164.20; P=0.02). An MPR was observed in 14 cases (87.5%; 95% CI: 64.0 to 97.8) within the neoCIT group, while three patients (20.0%; 95% CI: 7.0 to 45.2) were noted in the neoCT group, yielding an odds ratio of 28.00 (95% CI: 4.23 to 150.50; P<0.001). The median EFS was not achieved with neoCIT, while it was 19.0 months with neoCT (hazard ratio, 0.15; 95% CI: 0.04 to 0.62). The median OS was not reached for neoCIT, while it was 39.0 months for neoCT (hazard ratio, 0.23; 95% CI: 0.06 to 0.95). Grade 3 or 4 adverse events were observed in five patients in the neoCIT group (30.0%) and five in the control group (33.3%). Conclusions: Our study underscores the potential of neoadjuvant chemoimmunotherapy in resectable SCLC patients. The significant improvements in pCR, MPR, EFS, and OS compared to neoadjuvant chemotherapy alone offer a promising outlook for the future management of LS-SCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.